Alivus Life Sciences · NSE: ALIVUS · BSE: 543322
Q1 FY22 results · Apr–Jun 2021
Alivus Life Sciences reported revenue from operations of ₹524.90 crore and net profit of ₹100.91 crore for Q1 FY22 (Apr–Jun 2021), on a standalone basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 524.90 | — | — | — | — |
| Other income | 3.99 | — | — | — | — |
| Total income | 528.88 | — | — | — | — |
| Profit before tax | 134.97 | — | — | — | — |
| Net profit for the period | 100.91 | — | — | — | — |
| EPS, basic (₹) | 9.36 | — | — | — | — |
| Net margin (%) | 19.2 | — | — |
Standalone
- Filed with BSE
- 16 Aug 2021, 18:22 IST
- Board meeting
- 13 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE